Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2020 Edition).
10.3760/cma.j.cn112152-20201112-00981
- Collective Name:Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association;Expert Committee for Monitoring the Clinical Application of Antitumor Drugs;Breast Cancer Expert Committee of National Cancer Quality Control Center;Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center
- Publication Type:Systematic Review
- Keywords:
Antibody-drug conjugate;
Cytotoxic drug;
Malignant tumors;
Monoclonal antibody;
Safety management
- MeSH:
Antibodies, Monoclonal/therapeutic use*;
Antineoplastic Agents/therapeutic use*;
Consensus;
Humans;
Immunoconjugates/therapeutic use*;
Neoplasms/drug therapy*
- From:
Chinese Journal of Oncology
2021;43(1):78-91
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-drug conjugate (ADC) is a type of targeted biological agent which connect cytotoxic drug to monoclonal antibody by a connector head, which enables monoclonal antibody acted as a carrier to efficiently transport small molecular cytotoxic drugs to target tumor cells. It is very important for clinicians to have an in-depth understanding of the molecular characteristics and mechanism of ADC drugs, rationally choose the appropriate dose, course of treatment and manage adverse reactions according to the indications during the clinical application of ADC drugs, which may even affect the survival of patients. Therefore, the consensus aims to conduct a systematic overview of commercially available ADC drugs, provide effective recommendations and references for clinicians to better apply and manage ADC drugs.
